📣 VC round data is live. Check it out!

McKesson Valuation Multiples

Discover revenue and EBITDA valuation multiples for McKesson and similar public comparables like Parker Hannifin, Rheinmetall, Cencora, Grainger and more.

McKesson Overview

About McKesson

McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.


Founded

1994

HQ

United States

Employees

45.0K

Financials (LTM)

Revenue: $412B
EBITDA: $7B

EV

$105B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

McKesson Financials

McKesson reported last 12-month revenue of $412B and EBITDA of $7B.

In the same LTM period, McKesson generated $15B in gross profit, $7B in EBITDA, and $5B in net income.

Revenue (LTM)


McKesson P&L

In the most recent fiscal year, McKesson reported revenue of $359B and EBITDA of $5B.

McKesson is profitable as of last fiscal year, with gross margin of 4%, EBITDA margin of 1%, and net margin of 1%.

See analyst estimates for McKesson
LTMLast FY202320242025202620272028
Revenue$412B$359B$301B$347B$359B
Gross Profit$15B$13B$13B$13B$13B
Gross Margin4%4%4%4%4%
EBITDA$7B$5B$5B$5B$5B
EBITDA Margin2%1%2%1%1%
EBIT Margin2%1%1%1%1%
Net Profit$5B$3B$3B$3B$3B
Net Margin1%1%1%1%1%

Financial data powered by Morningstar, Inc.

McKesson Stock Performance

McKesson has current market cap of $100B, and enterprise value of $105B.

Market Cap Evolution


McKesson's stock price is $814.02.

McKesson share price decreased by 0.1% in the last 30 days, and increased by 13.1% in the last year.

McKesson has an EPS (earnings per share) of $26.90.

See more trading valuation data for McKesson
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$105B$100B0.0%-0.1%-17.6%13.1%$26.90

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

McKesson Valuation Multiples

McKesson trades at 0.3x EV/Revenue multiple, and 15.3x EV/EBITDA.

See NTM and 2027E valuation multiples for McKesson

EV / Revenue (LTM)


McKesson Financial Valuation Multiples

As of May 4, 2026, McKesson has market cap of $100B and EV of $105B.

McKesson has a P/E ratio of 20.4x.

LTMLast FY202320242025202620272028
EV/Revenue0.3x0.3x0.4x0.3x0.3x
EV/EBITDA15.3x20.0x21.6x20.6x20.0x
EV/EBIT16.4x21.9x24.7x22.6x21.9x
EV/Gross Profit7.2x7.9x8.3x8.0x7.9x
P/E20.4x30.3x31.7x30.9x30.3x
EV/FCF22.2x20.2x27.2x21.8x20.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified McKesson Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

McKesson Margins & Growth Rates

In the most recent fiscal year, McKesson reported gross margin of 4%, EBITDA margin of 1%, and net margin of 1%.

See estimated margins and future growth rates for McKesson

McKesson Margins

Last FY20242025202720282029
Gross Margin4%4%4%
EBITDA Margin1%1%1%
EBIT Margin1%1%1%
Net Margin1%1%1%
FCF Margin1%1%1%

McKesson Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth15%4%
Gross Profit Growth4%1%
EBITDA Growth5%3%
EBIT Growth9%3%
Net Profit Growth3%2%
FCF Growth25%8%

Data powered by FactSet, Inc. and Morningstar, Inc.

McKesson Operational KPIs

McKesson's revenue per employee in the last FY averaged $8.0M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for McKesson
LTMLast FY202320242025202620272028
Rule of 4010%
Bessemer Rule of X23%
Revenue per Employee$8.0M
Opex per Employee$0.2M
G&A Expenses to Revenue2%
Opex to Revenue2%3%2%2%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

McKesson Competitors

McKesson competitors include Parker Hannifin, Rheinmetall, Cencora, Grainger, Ferguson, Sumitomo, Fastenal, Cardinal Health and Sysco.

Most McKesson public comparables operate across Wholesale Distribution.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Parker Hannifin6.1x5.7x22.2x21.2x
Rheinmetall6.3x5.5x27.9x24.0x
Cencora0.2x0.2x16.7x12.3x
Grainger3.2x3.1x20.5x18.7x
Ferguson1.9x1.9x19.6x
Sumitomo1.5x1.5x11.1x17.7x
Fastenal6.3x6.1x28.1x27.1x

This data is available for Pro users. Sign up to see all McKesson competitors and their valuation data.

Start Free Trial

McKesson M&A Activity

McKesson has acquired 17 companies to date.

Last acquisition by McKesson was on August 26th 2024. McKesson acquired Core Ventures for $4B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by McKesson

Core Ventures
Compile
Glide Health
Glide Health
Description
Compile is a Boston-based healthcare data platform aggregating 70% of U.S. medical claims from 2015 onward plus Rx data. Healthgraph links patient treatments, HCPs, HCOs, and IDNs with public sources for lifecycle insights from market research to launch strategies. Pharmaceutical firms like Pfizer use it to map protocols and provider networks. Founded in 2018, Compile processes petabytes daily for commercial planning across 50 states.
Glide Health is a healthcare technology company offering AI-driven revenue cycle management. Its Intelligence platform analyzes financial and clinical data for predictions in patient registration, claims, denials, and collections, serving US hospitals and providers.
Glide Health is a cross-platform solution providing access to electronic medical records for patients, physicians, and healthcare providers on Android, BlackBerry, iPhone, Palm, Symbian, Windows Mobile, plus Windows, Mac, and Linux desktops. It synchronizes with existing EMR systems, allowing real-time updates of patient histories, appointments, prescriptions, and diagnostic images. Patients input personal health data, allergies, and medications, while collaboration tools enable secure sharing with doctors during travel or emergencies.
HQ CountryCentral African RepublicUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
San Francisco, CA
New York City, NY
Deal Date26 Aug 20244 Jan 202415 Feb 202315 Feb 2023
Valuation$4B$50Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all McKesson acquisitions and their M&A valuation multiples.

Start Free Trial

McKesson Investment Activity

McKesson has invested in 2 companies to date.

Latest investment by McKesson was on March 27th 2019. McKesson invested in Xealth in their $11M Series A round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by McKesson

Xealth
SHYFT
Description
Xealth is a Seattle-based digital health platform founded in 2015 that enables Providence Health and Kaiser Permanente to prescribe apps, wearables, and content from electronic health records. Providers recommend tools from a library of 300 vetted solutions, with patient data flowing back for analytics. The system tracks engagement across 50 organizations, optimizing care pathways for chronic diseases and wellness programs.
SHYFT is a Boston-headquartered analytics platform for life sciences companies. It integrates clinical trial data, real-world evidence, and commercial metrics to generate patient journey insights. SHYFT enables pharmaceutical firms to accelerate drug development and launch strategies by providing cross-functional analytics dashboards.
HQ CountryUnited StatesUnited States
HQ City
Seattle, WA
Boston, MA
Deal Date27 Mar 201929 Mar 2017
RoundSeries ASeries B
Raised$11M$8M
InvestorsAllumia Ventures; Froedtert Health; McKesson; Novartis; Philips Healthcare; Threshold; UPMCMcKesson; Medidata; Optum Ventures
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all McKesson investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About McKesson

When was McKesson founded?McKesson was founded in 1994.
Where is McKesson headquartered?McKesson is headquartered in United States.
How many employees does McKesson have?As of today, McKesson has over 45K employees.
Who is the CEO of McKesson?McKesson's CEO is Brian S. Tyler.
Is McKesson publicly listed?Yes, McKesson is a public company listed on NYSE.
What is the stock symbol of McKesson?McKesson trades under MCK ticker.
When did McKesson go public?McKesson went public in 1987.
Who are competitors of McKesson?McKesson main competitors include Parker Hannifin, Rheinmetall, Cencora, Grainger, Ferguson, Sumitomo, Fastenal, Cardinal Health, Sysco.
What is the current market cap of McKesson?McKesson's current market cap is $100B.
What is the current revenue of McKesson?McKesson's last 12 months revenue is $412B.
What is the current revenue growth of McKesson?McKesson revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of McKesson?Current revenue multiple of McKesson is 0.3x.
Is McKesson profitable?Yes, McKesson is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of McKesson?McKesson's last 12 months EBITDA is $7B.
What is McKesson's EBITDA margin?McKesson's last 12 months EBITDA margin is 2%.
What is the current EV/EBITDA multiple of McKesson?Current EBITDA multiple of McKesson is 15.3x.
What is the current FCF of McKesson?McKesson's last 12 months FCF is $5B.
What is McKesson's FCF margin?McKesson's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of McKesson?Current FCF multiple of McKesson is 22.2x.
How many companies McKesson has acquired to date?As of May 2026, McKesson has acquired 17 companies.
What was the largest acquisition by McKesson?$4B acquisition of Core Ventures on 26th August 2024 was the largest M&A McKesson has done to date.
What companies McKesson acquired?McKesson acquired Core Ventures, Rexall, CoverMyMeds, Vantage Oncology, Rx Savings Solutions, Medical Specialties Distributors, RxCrossroads, Biologics, UDG Healthcare, intraFUSION, and 7 other companies.
In how many companies McKesson has invested to date?As of May 2026, McKesson has invested in 2 companies.
What was the last McKesson investment?On 27th March 2019 McKesson invested in Xealth, participating in a $11M Series A round, alongside Allumia Ventures, Froedtert Health, Novartis, Philips Healthcare, Threshold, and UPMC.
In what companies McKesson invested in?McKesson invested in Xealth and SHYFT.

See public comps similar to McKesson

Lists including McKesson

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial